-Reuters
Erasca Announces Two Clinical Trial Collaboration And Supply Agreements For Trametinib To Evaluate Naporafenib Combination In SEACRAFT-1 And SEACRAFT-2 Trials
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4